


# PRODUCT INFORMATION



## Pimodivir

Item No. 29321

**CAS Registry No.:** 1629869-44-8  
**Formal Name:** (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-bicyclo[2.2.2]octane-2-carboxylic acid  
**Synonyms:** JNJ 63623872, JNJ 872, VX 787  
**MF:** C<sub>20</sub>H<sub>19</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>  
**FW:** 399.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 222, 263 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Pimodivir is supplied as a solid. A stock solution may be made by dissolving the pimodivir in the solvent of choice, which should be purged with an inert gas. Pimodivir is soluble in the organic solvent DMSO.

### Description

Pimodivir is an inhibitor of influenza virus polymerase basic protein 2 (PB2;  $K_D = <0.003 \mu\text{M}$ ).<sup>1</sup> It also binds to glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ;  $K_i = \sim 1.6 \mu\text{M}$ ) and inhibits the activity of Axl and calcium/calmodulin-dependent protein kinase II $\beta$  (CaMKII $\beta$ ) by greater than 50% in a panel of 65 human and rat kinases. Pimodivir decreases the replication of seven adamantine- and neuraminidase inhibitor-resistant strains of influenza virus A ( $EC_{50}$ s = <0.15-2.8 nM in a cell-based assay). It increases the antiviral activity of oseltamivir (Item No. 16070), zanamivir (Item No. 15123), and favipiravir (T-705; Item No. 23384) with 50% combination index ( $CI_{50}$ ) values of 0.58, 0.64, and 0.89, respectively, in a cell-based assay.<sup>2</sup> Pimodivir increases survival in a mouse model of intranasal influenza A infection when administered at doses of 1, 3, and 10 mg/kg twice per day.

### References

1. Clark, M.P., Ledebor, M.W., Davies, I., *et al.* Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. *J. Med. Chem.* **57**(15), 6668-6678 (2014).
2. Byrn, R.A., Jones, S.M., Bennett, H.B., *et al.* Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. *Antimicrob. Agents Chemother.* **59**(3), 1569-1582 (2014).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/21/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM